Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?

2 hours ago 1

Robert Izquierdo, The Motley Fool

Sat, January 24, 2026 astatine 3:11 PM CST 4 min read

Palisades added 137,768 shares of Travere Therapeutics; estimated commercialized size $5.26 cardinal based connected quarterly mean price.
The presumption represents 1.99% of 13F assets nether absorption (AUM).
Travere Therapeutics is not among the fund’s apical 5 holdings aft the trade.
These 10 stocks could mint the adjacent question of millionaires ›

According to a Securities and Exchange Commission (SEC) filing dated January 20, 2026, Palisades Investment Partners, LLC reported initiating a caller presumption successful Travere Therapeutics (NASDAQ:TVTX).

The money acquired 137,768 shares, with the estimated worth of the commercialized astatine $5.26 cardinal based connected the quarterly mean stock price. The caller stake’s quarter-end worth besides totaled $5.26 million, reflecting the company’s stock terms astatine play close.

This caller presumption accounts for 1.99% of Palisades Investment Partners’ $264.72 cardinal successful reportable U.S. equity assets arsenic of December 31, 2025

Top 5 holdings aft the filing:

NASDAQ: STRL: $29.86 cardinal (11.3% of AUM)
NYSE: SPXC: $23.04 cardinal (8.7% of AUM)
NASDAQ: WGS: $11.34 cardinal (4.3% of AUM)
NASDAQ: KRYS: $10.54 cardinal (4.0% of AUM)
NASDAQ: MMYT: $9.80 cardinal (3.7% of AUM)

As of January 19, 2026, Travere Therapeutics shares were priced astatine $27.87, up 50.89% implicit the past twelvemonth and outperforming the S&P 500 by 34.01 percent points.

Metric

Value

Price (as of marketplace adjacent January 16, 2026)	$27.87
Market Cap	$2.46 billion
Revenue (TTM)	$435.83 million
Net Income (TTM)	($88.54 million)

Travere Therapeutics generates gross from commercialized uncommon illness therapies, including Chenodal, Cholbam, and Thiola/Thiola EC, with further pipeline assets specified arsenic Sparsentan and TVT-058 successful objective development.
The institution operates a biopharmaceutical concern model, focusing connected the identification, development, and commercialization of treatments for uncommon and specialty diseases, leveraging proprietary probe and strategical collaborations.
Travere Therapeutics serves patients with uncommon metabolic and renal disorders, targeting high-need indications done partnerships with advocacy organizations and probe institutions.

Travere Therapeutics, Inc. is simply a biotechnology institution specializing successful the improvement and commercialization of therapies for uncommon diseases. The institution leverages a diversified portfolio of approved products and a pipeline targeting high-need indications, supported by strategical partnerships and objective probe initiatives.

Travere's absorption connected uncommon illness markets positions it to code unmet aesculapian needs and thrust maturation done targeted innovation and commercialization.